Skip to content

Plain-English explainer

Does Semaglutide Cause Hair Loss? (And Does It Grow Back?)

By Updated

Sources linked below.

On this page

Featured partner

CoreAge Rx

$99/mo flat

Doctor-reviewed semaglutide with one flat price and built-in human support.

Check availability
Category
Telehealth · semaglutide
Pricing
Flat monthly price
Support
Nurse + dietitian consults
Labs
No labs required

Advertising disclosure · we may earn a commission at no extra cost to you.

Partner

Sprout Health

Compounded semaglutide at one price for every dose, billed every four weeks or prepaid for a year, with the visit, medication and shipping in that price.

$149 per 4 weeks · $99/mo on 12 months

Check Sprout Health availability

FDA warning letter

The FDA issued a warning letter to Sprout Health Partners LLC dba Sprout Health in September 2025. It is on the public record in the FDA's warning-letter database, which we link rather than summarize. FDA warning-letter database ↗

Hair loss was reported more often with Wegovy than placebo in weight-management trials. In the adult trials of the 2.4 mg weekly injection, the prescribing information reports 3% versus 1%1. That finding establishes an association with treatment. It does not prove that every case is temporary shedding or rule out other causes of hair loss.

How common is it?

The 3% figure applies to the adult 2.4 mg injection trials, not every dose or semaglutide product. The current label also describes other study populations and formulations, so check which treatment a quoted number refers to1.

A trial rate is useful context if you are deciding what to watch for. It cannot tell you whether your own thinning is caused by treatment, weight loss, a nutritional deficiency, or a separate scalp condition.

Evidence and limits
Keep the observed reaction separate from the proposed explanation.

Telogen effluvium is diffuse shedding after a change in the hair-growth cycle. Weight loss is a recognized trigger. A retrospective dermatology study followed 140 people diagnosed with weight-loss-associated telogen effluvium; the investigators reported improvement during follow-up2.

That study was not a semaglutide trial. It supports weight loss as one possible explanation, but cannot establish what proportion of Wegovy-associated hair loss has that cause. Reviews of GLP-1-associated hair loss discuss this possibility while noting limits in the available evidence3. Spontaneous adverse-event reports also cannot prove the mechanism or estimate the risk in everyone taking a drug4.

Will it grow back?

Acute telogen effluvium can improve as the trigger resolves, but a diagnosis matters before predicting regrowth. The weight-loss study found variable recovery times; it cannot provide a personal recovery deadline2. Hair loss may also have more than one cause.

Arrange a clinical review if shedding is persistent, if you see bald patches, or if you have scalp pain, inflammation, or scarring. Do not assume every change during treatment is the same form of shedding.

Before your appointment

What to discuss with your clinician

Bring a timeline of when treatment began, dose changes, weight change, and when shedding started. Include other medicines, recent illness, and any major change in eating. These details help your clinician decide whether examination or testing is useful.

If your appetite makes meals difficult, discuss your food intake rather than adding supplements at random. Our protein on semaglutide guide explains meal planning; the muscle-loss guide covers another reason to pay attention to nutrition during weight loss. A protein target is not a proven treatment for every kind of hair loss.

Do not increase, reduce, or stop semaglutide on your own to manage shedding. The label's dose-escalation schedule manages treatment tolerability; it has not been shown to prevent hair loss1. Your prescriber can weigh the severity of the problem against your treatment benefits and alternatives. Read what happens when you stop semaglutide before that conversation.

What the evidence can tell you

Hair loss is a documented adverse reaction, and weight-related shedding is a plausible contributor. The evidence does not support promising that it is always reversible, that the drug plays no direct role, or that continuing unchanged is right for everyone.

For a broader overview, see semaglutide: how it works, results and side effects. Our provider guide explains what to ask about access to clinical follow-up.

A few more quick ones

How common is hair loss on Wegovy?

In adult weight-management trials of the 2.4 mg weekly injection, hair loss was reported in 3% receiving Wegovy and 1% receiving placebo. Rates differ across populations and formulations.

Is all hair loss during semaglutide treatment telogen effluvium?

No. Weight-related telogen effluvium is one possible cause. The trials do not establish that it explains every case, and a clinician may need to check other causes.

Will my hair grow back?

Acute telogen effluvium can improve, but regrowth depends on the cause. The available evidence cannot promise a recovery date for an individual taking semaglutide.

Should I stop semaglutide if my hair is thinning?

Discuss the change with your prescriber before altering treatment. Do not assume that stopping is necessary or that continuing unchanged is always appropriate.

Does slower titration prevent hair loss?

That has not been established. The labeled escalation schedule addresses tolerability; it should not be presented as a proven hair-loss prevention strategy.

Where this comes from

Sources include clinical studies, official labeling, and company pricing pages. Company-source links below lead to our provider pricing and source checks.

  1. Novo Nordisk (2026). Wegovy prescribing information — adverse reactions. FDA-approved prescribing information. https://www.novo-pi.com/wegovy.pdf
  2. Kang DH, Kwon SH, Sim WY, Lew BL (2024). Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Annals of Dermatology. https://pmc.ncbi.nlm.nih.gov/articles/PMC11621640/
  3. Alsuwailem OA, Alanazi R, Almutairi HM, et al. (2025). Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. Cureus. https://pubmed.ncbi.nlm.nih.gov/41111833/
  4. Fat MN, Johnson HC, Farberg AS, et al. (2026). Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024. J Drugs Dermatol. https://pubmed.ncbi.nlm.nih.gov/41493256/
  5. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. https://pubmed.ncbi.nlm.nih.gov/33567185/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.